Diffuse midline glioma, H3 K27-altered, is one of the most aggressive tumor entities recognized by the World Health Organization Classification of Central Nervous System Tumors. These tumors arise in midline structures of the brain and spinal cord, including the brainstem, thalamus and spinal cord, and they carry a prognosis that remains grim despite decades of clinical trials. The defining molecular feature of the entity is disruption of polycomb repressive complex 2 function at lysine 27 of histone H3, which manifests either as the canonical K27M oncohistone substitution in H3.3 or H3.1, or as overexpression of EZHIP, a protein that mimics the inhibitory effect of the mutant histone on the methyltransferase complex. The downstream consequence is a characteristic global reduction of tri-methylated lysine 27, detectable in diagnostic sections as loss of nuclear H3K27me3 immunostaining in tumor cells, with retained staining in internal control elements such as endothelial cells and infiltrating lymphocytes.

The original study by Tauziède-Espariat and colleagues, which prompted the commentary, reported cases in which this hallmark loss of H3K27me3 staining was present even though the tumors harbored neither H3K27M mutations nor EZHIP expression. The authors of that study flagged the finding as a potential diagnostic pitfall, because current diagnostic algorithms often treat the combination of midline location and H3K27me3 immunoloss as presumptive evidence of H3 K27-alteration, frequently in the absence of confirmatory sequencing. In the absence of the two canonical drivers, the mechanism underlying the epigenetic silencing of the mark remained opaque, leaving open the question of whether such tumors truly belong to the H3 K27-altered category or represent a separate, still-undefined process.

The Moscow-based commentators propose an explanation grounded in the biophysics of the histone H3 amino-terminal tail. The lysine 27 residue sits within a short stretch of the tail that also contains serine 28, immediately adjacent to the methylated lysine, and serine 31, located just a few residues downstream. Both serines are functionally important phosphorylation sites. Serine 28 phosphorylation by Aurora kinase B is classically associated with mitotic chromosome condensation, while phosphorylation of serine 31 in the H3.3 variant has been linked to chromosome segregation fidelity, p53-dependent cell cycle arrest after missegregation, enhancer acetylation through activation of the p300 coactivator, and the regulation of nucleosome dynamics during transcription. Recent work summarized in the commentary indicates that K27M oncohistones suppress serine 31 phosphorylation and that this suppression can itself contribute to gliomagenesis, underscoring how tightly the biology of these neighboring residues is interwoven with tumor formation.

Against this background, the commentators draw attention to tumor sequencing data in which H3 K27-altered diffuse midline gliomas carried additional, concurrent substitutions converting serine 28 to cysteine, or serine 31 to cysteine or tyrosine. These are not random passengers, they argue, but may reflect a mutation bias inherent to the biology of the tumor. One plausible mechanism is the altered local chromatin environment created by K27-alteration itself: the loss of polycomb-mediated repression and the resulting transcriptional deregulation can expose the H3-encoding genes, particularly the replication-independent H3.3 variant genes H3F3A and H3F3B, to error-prone repair or to the activity of error-prone polymerases. Because codons for serine 28 and serine 31 are chemically primed for specific single-base substitutions, cysteine and tyrosine represent favored conversion products, and their recurrent appearance in the same tumors that alter lysine 27 is unlikely to be coincidental.

The functional implications of such substitutions are potentially profound. Replacing a phosphorylatable serine with cysteine or tyrosine permanently abolishes that phosphorylation site, mimicking a non-phosphorylatable state that cannot be dynamically regulated by kinases. In the case of serine 31, evidence from model systems shows that loss of H3.3 S31 phosphorylation disrupts mitotic fidelity and promotes chromosomal instability, a hallmark of high-grade gliomas. In the case of serine 28, studies in Drosophila and in mammalian cells demonstrate that this residue is essential for efficient polycomb-mediated gene repression and that its modification state influences heterochromatin formation through effects on H3K9 and H3K36 demethylases. A tumor cell in which both lysine 27 methylation is disabled and neighboring serines are locked into non-phosphorylatable states would therefore accumulate multiple converging disruptions of the same regulatory hub, potentially reinforcing the oncogenic chromatin program.

The diagnostic dimension of the argument is where the commentary acquires its practical urgency. Commercial diagnostic antibodies against H3K27M and against other mutant H3 epitopes depend on precise recognition of short amino acid sequences surrounding the substituted residue. Substitutions in immediately adjacent residues, such as S28C, which sits directly beside lysine 27, or S31C and S31Y, can alter the local epitope landscape. Depending on the antibody clone and its epitope, such a change could either weaken binding and produce a false-negative result, or in some assay contexts generate aberrant or ambiguous staining patterns. A laboratory that interprets an unexpected immunoprofile at face value, without sequencing, could misclassify a tumor, and given that diffuse midline glioma is frequently diagnosed on small stereotactic or open biopsies where tissue is scarce, the margin for error is narrow.

The commentators therefore recommend a disciplined diagnostic pathway. When a midline glioma shows loss of H3K27me3 but is negative for H3K27M by immunostaining or sequencing, and EZHIP overexpression is absent, the possibility of concurrent histone tail substitutions should be actively considered. Targeted sequencing of the H3F3A and H3F3B loci, ideally with coverage capable of detecting co-occurring variants on the same allele or on separate histone gene copies, can resolve the ambiguity. Methylation profiling, now regarded as an increasingly essential adjunct in central nervous system tumor diagnostics, can provide independent support for assigning such tumors to the H3 K27-altered diffuse midline glioma class, since the methylation signature of the entity appears to be preserved even when individual driver assays behave unpredictably. Integration of histopathology, immunohistochemistry, sequencing and methylation classification, rather than reliance on any single test, emerges as the central lesson.

Beyond the diagnostic clinic, the observation raises broader questions about how oncohistone tumors evolve. If K27-alteration biases the histone tail toward further substitutions at serine 28 and serine 31, then the canonical model of a single dominant oncohistone mutation may be incomplete, and the H3 tail may function as a recurrent mutational hotspot whose successive hits progressively dismantle polycomb regulation and mitotic control. The commentators, whose work was supported by the Foundation for support and development in the field of pediatric hematology, oncology and immunology Science for Children and approved by the ethics committee of the Dmitry Rogachev Center, frame their argument as a call to the neuropathology community to recognize that H3K27me3 loss without canonical drivers is not necessarily an artifact but a window into an additional layer of histone biology. For a disease in which molecular classification currently drives eligibility for targeted trials, distinguishing true biological complexity from mere diagnostic noise may determine which patients receive the right investigational therapy, and the serine residues flanking the infamous lysine 27 have now moved from biochemical footnotes to the center of that conversation.

Subject of Research: Concurrent histone H3 S28C and S31C/Y substitutions in H3 K27-altered diffuse midline gliomas and their impact on diagnosis

Article Title: Concurrent substitutions H3 S28C or S31C/Y in H3 K27-altered diffuse midline gliomas may represent mutation bias, apart from being a source of potential diagnostic pitfall. Scientific commentary on: “H3K27ME3 loss in diffuse midline gliomas lacking H3K27M or EZHIP expressions, a potential diagnostic pitfall!”

Article References: Zaytseva, M., Papusha, L., & Druy, A. (2026). Concurrent substitutions H3 S28C or S31C/Y in H3 K27-altered diffuse midline gliomas may represent mutation bias, apart from being a source of potential diagnostic pitfall. Scientific commentary on: “H3K27ME3 loss in diffuse midline gliomas lacking H3K27M or EZHIP expressions, a potential diagnostic pitfall!”. Acta Neuropathologica, 152(1), Article 33. https://doi.org/10.1007/s00401-026-03083-6

Image Credits: AI Generated

DOI: 10.1007/s00401-026-03083-6

Keywords: diffuse midline glioma, histone H3, H3K27me3, H3K27M, EZHIP, oncohistone, serine 28, serine 31, polycomb repressive complex 2, diagnostic pitfall, neuropathology, brain tumor